Comparative Analysis of Antithrombotic Therapy Outcomes in Mild Traumatic Brain-Injury Patients: A Focus on Bleeding Risk and Hospital-Stay Duration

• Published in: Life (Basel, Switzerland) Vol. 14; no. 3; p. 308
• Main Authors: Desai, Antonio, Shiffer, Dana, Giordano, Mauro, Giotta Lucifero, Alice, Generali, Elena, Reggiani, Francesco, Calatroni, Marta, Savioli, Gabriele, Luzzi, Sabino, Voza, Antonio
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 27.02.2024; MDPI
• Subjects: Age; Aging; Anticoagulants; Aspirin; Bleeding; Brain; Brain research; Cardiac arrhythmia; Comparative analysis; Complications and side effects; Creatinine; Diabetes; Drugs; elderly patients; Emergency medical care; Emergency medical services; FDA approval; Fish diseases; Head injuries; Health aspects; Hematoma; Hemoglobin; Hemorrhage; Heparin; Hospitals; Injuries; Injury analysis; Intervention; intracranial bleeding; length of hospitalization; Length of stay; Mortality; Patient outcomes; Patients; Regression analysis; Regression models; Statistical analysis; Statistics; Therapy; Thrombolytic drugs; Traumatic brain injury; Italy; anticoagulants; traumatic brain injury; elderly patients; aspirin; intracranial bleeding; length of hospitalization
• DOI: 10.3390/life14030308
• ISSN: 2075-1729

Traumatic brain injury (TBI) in the elderly is a noteworthy pathology due to the exponential increase in population age, and the effects of antiplatelet and anticoagulation on patients' outcomes are still a matter of dispute. The aim of the present study was to evaluate the impact of various antithrombotic agents on patients with mild TBI, focusing on the risk of intracranial bleeding (ICH) and length of hospitalization (LOS). A retrospective analysis was conducted, including patients with a diagnosis of TBI admitted to the Emergency Department between 2021 and 2022. Patients were classified according to the concurrent antithrombotic therapy as aspirin (ASA), antiplatelets, direct oral anticoagulants (DOACs), and low-molecular-weight heparin (LMWH). The primary outcome was the ICH occurrence, while the secondary outcome was the LOS. The statistical analysis was performed via logistic regression models in R and STATA 13.1 software. Fisher's exact test was used for the statistical significance. 267 patients with mild TBI were included; 148 were not on antithrombotic agents, 43 were on aspirin, 33 on DOACs, 5 on LMWH, 22 on antiplatelets, and 16 on VKA. Out of the total, 9 patients experienced ICH, none of which were on DOACs, LMWH, or VKA, but 4-out of 65-were on antiplatelets, and 5-out of 148-were not on antithrombotic therapies. Patients not on antithrombotic therapy had the shortest LOS at 0.46 days, while those on VKA had the longest LOS at 1.19 days; similar trends were observed for patients on DOAC and LMWH. The results reveal that TBI patients on anticoagulants/antiplatelets had longer hospital stays compared with those on aspirin alone. Notably, VKA was the strongest predictor for an extended LOS. Regarding ICH, patients taking only aspirin were twice as likely to experience bleeding compared with those on anticoagulants/antiplatelets. However, to achieve statistically significant evidence, further research with a larger cohort of patients is needed.